Glycoflo Neb 25mcg/2ml Transpules

Glycopyrrolate acts by selectively antagonizing muscarinic receptors in the airway smooth muscle, leading to bronchodilation and reduced mucus secretion, thereby improving airflow and respiratory function. It is particularly beneficial in patients requiring maintenance bronchodilator therapy to prevent exacerbations and improve quality of life. The nebulized formulation allows for direct deposition into the lungs, facilitating rapid onset of action with minimal systemic absorption and reduced risk of anticholinergic side effects.

Glycoflo Neb is administered via a nebulizer device, with dosing tailored according to clinical response and severity of symptoms. Common adverse effects may include dry mouth, throat irritation, and occasional cough. Caution is advised in patients with hypersensitivity to Glycopyrrolate or other anticholinergic agents, narrow-angle glaucoma, or urinary retention. Glycoflo Neb should be used under medical supervision with regular monitoring to optimize therapeutic outcomes.